Aims To assess the relationship between antihypertensive therapy and malignancy.
Introduction
Antihypertensive treatment has been shown to decrease cardiovascular morbidity and mortality [1] [2] [3] [4] [5] . Despite the universal findings of decreased cardiovascular morbidity and mortality, not all studies showed a significant decrease in total mortality [1] [2] [3] [4] [5] . It might be explained either by dilution of the above through lack of association between antihypertensive therapy and other causes of mortality, or by relative increase in non-cardiovascular mortality in treated hypertensive patients. Malignancy is one of the most common extra-cardiovascular causes of death. Thus, it is conceivable that treated hypertensive patients die of malignancies in greater proportion than non-treated patients. Several antihypertensive agents have been implicated in increasing the incidence and mortality from malignancy
Methods

Literature search
A MEDLINE search of English-language articles, published between 1966 and August 1999, was conducted using the terms cardiovascular agents or drug therapy or antihypertensive agents, and neoplasm or cancer or malignancy. References from identified articles were also reviewed. From the 213 identified articles, we included prospective studies only if they reported cancer incidence or mortality in antihypertensive drug users and non-users, and case-control studies that reported the frequency of specific drug use in cancer patients and controls. Fifty seven studies fulfilled the criteria for inclusion. They were classified as case control (n=28), longitudinal (n=19), or randomized controlled (n=10) studies (Table 1) .
Statistical analysis
We pooled study-specific estimates of the odds ratios of malignancy, to provide a pooled odds ratio and a confidence interval, using the Cochran-MantelHaenszel and maximum likelihood estimates for a combined odds ratio. We applied two PEPI (Programs for Epidemiologic Analysis) programmes CASECONT and COMBINE [63] to combine measures of associations, either from 2 2 tables or reported odds ratios and hazard ratios from the different studies. The programmes provide the chi square test of association and tests for heterogeneity between individual studies. If heterogeneity is significant, an alternative estimate (the Laird DeSimonian model) for a pooled odds ratio is calculated.
We avoided combining estimates from different designs. Biases inherent in case-control design are different from observational longitudinal designs. Neither can isolate indication and detection biases, which might occur when an individual patient has been prescribed therapy on grounds that are not fully recorded as variables that can be adjusted for. Case-control comparisons are also sensitive to survival, recall and response biases. Thus, residual confounding is ample in comparative non-randomized follow-up of users and non-users of a given drug. In randomized controlled trails these biases are removed. It is possible that these trials provide distinctly different estimates. The statistical methods used were described by Fleiss [64] .
Results
Reserpine and breast cancer
We identified 14 case-control studies that reported rauwolfia derivative use in breast cancer patients and controls ( Fig. 1 ) [6, 15, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . A meta-analysis of all published case-control studies, including a total of 5852 cases of breast cancer and 9776 controls, yielded an odds ratio of 1·25 (95% CI, 1·09-1·44). Three prospective studies [37] [38] [39] failed to confirm an excess rate of breast cancer in reserpine users. In the Hypertension Detection and Follow-Up Program (HDFP) a total of 2529 females were followed for 5 years in the Stepped Care group. Of this group, 1036 received reserpine with an average exposure of 1·97 years. The risk ratio for breast cancer in those who took reserpine in comparison to those who did not was 1·28 (95% CI, 0·58-2·80) [38] , consistent with the above estimate based on metaanalysis of the case control studies.
Diuretics
Thirteen clinical studies, three cohort and 10 casecontrol ones, evaluated the association between the use of diuretics and renal cell carcinoma. The 10 casecontrol studies included a total of 4389 cases of renal cell carcinoma and 6566 controls, and the three cohort studies included 1 226 229 patients with 802 cases of renal cell carcinoma. In all case control studies, the odds were greater for users of diuretics [9, 11, 12, [17] [18] [19] [20] [21] 40, 41] , with a pooled odds ratio of 1·54 (95% CI, 1·41 to 1·68) ( Table  2 ). In six case-control studies the results were given for men [9, 17, 18, 21, 40, 41] and in eight studies the results were given for women [9, [17] [18] [19] [20] [21] 40, 41] (Table 3 ). The odds ratio for renal cell carcinoma among users of diuretics relative to non-users was 2·03 (95% CI, 1·71 to 2·40) in women and 1·58 (95% CI, 1·28 to 1·94) in men, respectively.
The relationship between diuretic use and renal cell carcinoma was further confirmed in three cohort studies comprising a population of 1 226 229 patients [16, 42, 43] ( Table 2) . In these studies, the pooled age-adjusted risk ratio related to diuretic use was 2·00 (95% CI, 1·55-2·59). The use of diuretics was associated with an increase in the age-adjusted risk for fatal renal cell carcinoma in women, where the pooled ratio was 2·43 (95% CI, 2·13 to 2·78), but not in men (risk ratio 1·29; 95% CI, 0·42-3·97).
Beta-blockers
We identified three randomized controlled trials that reported cancer mortality in hypertensive patients treated with atenolol [3, 44, 45] . In the Medical Research Council's randomized trial of elderly hypertensive patients, men receiving atenolol exhibited an almost twofold higher death rate from lung cancer than those receiving a diuretic or placebo [3] . This was not observed in women receiving atenolol, whose lung cancer mortality was similar to those receiving a diuretic and lower than those receiving placebo. Coope and Warrender, in a randomized controlled trial of elderly hypertensive patients in a primary care setting, reported an excess of fatal lung cancers in the group given atenolol compared with the control group (odds ratio of 1·89; 95% CI, 0·88 to 4·08) [44] . In the United Kingdom Prospective Diabetes Study (UKPDS), a prospective randomized controlled trial of diabetic hypertensive patients, those receiving atenolol exhibited a higher death rate from cancer than those receiving captopril (odds ratio of 1·87; 95% CI, 0·83 to 4·30) [45] . A meta-analysis of these three prospective randomized controlled trials, including 1879 [15] 1974 Case control Reserpine Armstrong et al. [25] 1974
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patients receiving atenolol and 3078 patients not receiving atenolol showed an increased rate of cancer death in those receiving atenolol with a pooled odds ratio of 1·36 (95% CI, 1·02-1·82). In one case-control study [9] , the use of beta-blockers was associated with renal cell carcinoma in women (risk ratio of 1·8, 95% CI, 1·0-3·2). In contrast to the above observations, one longitudinal study and three case control studies found no
No author listed [15] Armstrong et al. [25] Heinonen et al. [26] Mack TM et al [27] O'Fallon et al. [28] Laska et al. [29] Armstrong et al. [30] Lilienfeld et al. [31] Aromaa et al. [32] Kewitz et al. [33] Christopher et al. [34] Williams et al. [6] Kodlin and McCarthy [35] Shapiro et al. [36] Figure 1 Case control studies relating breast cancer to rauwolfia derivatives. Yu et al. [40] 1986 34/126 20/140 1·89 (0·99-3·61) McCredie and Stewart [9] 1992 175/314 154/369 1·34 (1·02-1·75) Finkle et al. [19] 1993 116/75 63/128 3·14 (2·02-4·89) Kreiger et al. [17] 1993 76/437 109/1260 2·01 (1·45-2·78) Hiatt et al. [20] 1994 49/40 32/57 2·18 (1·14-4·17) Weinmann et al. [21] 1994 93/113 99/193 1·60 (1·09-2·35) Mellemgaard et al. [18] 1994 107/261 92/304 1·35 (0·97-1·90) McLaughlin et al. [11] 1995 501/1229 515/1792 1·42 (1·23-1·64) Chow et al. [12] 1995 157/282 186/503 1·51 (1·15-1·96) Shapiro et al. [41] association between use of beta-blockers and malignancy [14, [46] [47] [48] . Hole et al. [46] found that in hypertensive patients neither men nor women taking atenolol experienced an increased rate of cancer mortality. However, subgroup analysis showed that non-smoking men receiving atenolol had a significantly increased risk of dying of malignancy (relative risk, 1·58). Moreover, in a subgroup of elderly patients receiving beta-blockers, other than atenolol, a 76% excess of malignancy incidence was observed. Renal cell carcinoma was the only type to be significantly increased. Fletcher et al. [47] reported that patients receiving atenolol experience the same mortality from cancer as those not receiving atenolol. The only excess standardized mortality ratio was for renal cancer.
Calcium antagonists
In one small study of 750 elderly hypertensive patients, followed for 4 years, the use of short-acting calcium antagonists, as a group, was associated with increased risk for malignancy in comparison to use of betablockers (relative risk of 2·02; 95% CI, 1·16-3·54) [22] . These patients represented part of an observational cohort study of 5052 people, aged 71 years or above, in which the adjusted hazard ratio for cancer associated with calcium antagonists was 1·72 (95% CI, 1·27-2·34) [23] . In the Cardiovascular Health Study, in which the data of 3198 elderly women (age d65 years) were analysed, an elevated risk of breast carcinoma was observed in users of calcium antagonists (hazard ratio of 2·57; 95% CI, 1·47-4·49) [24] . This association was enhanced when a high dose was used at baseline, and when calcium antagonists were combined with oestrogen, and persisted when the comparison group was users of other antihypertensive medication.
In contrast to the above observations, several studies found no association between calcium antagonist use and malignancy [14, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] 65] . Two large case-control studies [14, 48] including 9301 patients with malignancy and 7761 controls showed no association between use of calcium antagonists and malignancy. The combined odds ratio for both studies was 1·02 (95% CI, 0·91-1·13). A meta-analysis of five longitudinal studies, including 9087 calcium antagonist users and 15 559 non-users, shows an identical risk for malignancy among calcium antagonist users when compared to non-users ( Fig. 2 
) (odds ratio of 1·04; 95% CI, 0·91-1·19).
A meta-analysis of five randomized controlled trials, including 5451 calcium antagonists users and 5207 nonusers followed for several years, shows a lower risk for malignancy among calcium antagonist users when compared to non-users (Fig. 2) (odds ratio of 0·78; 95% CI, 0·60-1·00).
In addition, in one recent study Olsen et al. identified 412 cancers among 17 911 individuals who received at least one prescription of calcium antagonist and were followed for 3 years in Denmark. This number was identical to that expected on the basis of rates from the Danish Cancer registry [57] .
Angiotensin converting enzyme (ACE) inhibitors
In the Studies of Left Ventricular Dysfunction (SOLVD), a prospective randomized controlled trial of patients with congestive heart failure, followed for an average duration of 41·4 months, those who received enalapril had a slightly higher incidence of malignancy than those who received placebo (odds ratio of 1·59; 95% CI, 0·90 to 2·82) [58] . In another prospective randomized controlled trial of 583 patients with renal insufficiency, followed for 3 years, those who received benazepril exhibited a slightly higher incidence of malignancy than did those who received placebo (odds ratio of 1·52; 95% CI, 0·45 to 5·42) [59] . Meta-analysis of the two randomized controlled trials, including 1585 patients receiving ACE inhibitors and 1567 patients not receiving ACE inhibitors, showed increased incidence of malignancy in those receiving ACE inhibitors with a pooled odds ratio of 1·57 (95% CI, 0·97-2·57). Unlike these reports, other studies showed no relationship between use of ACE inhibitors and malignancy [14, 18, 22, 24, 48] . [19] 116/ 75 63/128 3·14 (2·02-4·89) Kreiger et al. [17] 31/281 35/628 45/156 74/631 1·98 (1·16-3·37) 2·46 (1·6-3·78) Hiatt et al. [20] 49/40 32/57 2·18 (1·14-4·17) Weinmann et al. [21] 
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In a recent longitudinal study, long-term use of ACE inhibitors protected against malignancy [60] . In this study the relative risks of incidence and fatal cancer among patients receiving ACE inhibitors compared with controls were 0·72 (95% CI, 0·55-0·92) and 0·65 (95% CI, 0·44-0·93), respectively.
Other antihypertensive agents and cancer
One case report was described where methyldopa was associated with lymphoproliferative disorders [66] . In one retrospective study [67] of 82 patients with biliary carcinoma, a higher than expected prevalence of methyldopa therapy was found. However, a subsequent study [68] failed to confirm this association. Two case-control studies found no relationship between methyldopa use and breast cancer [31, 32] . In case-control studies, no association was found between hydralazine use and either breast cancer [61] or lung and colorectal cancers [62] . One small study of the relationship between use of alpha blockers and renal cell carcinoma showed no association [18] .
Discussion
Several studies raised the possibility that antihypertensive treatment may increase the rate of malignancy. A drug may increase the risk of malignancy either by being directly carcinogenic, by eliciting or accelerating other carcinogens, or by impeding defence mechanisms. Many clinical studies tried to determine whether antihypertensive drugs, in general, are carcinogenic [6] [7] [8] [9] [10] [11] [12] [13] [14] 69] . In the present study, we evaluated by meta-analysis the association between various antihypertensive drug classes and cancer. For diuretics and reserpine, the findings might be subjected to uncontrolled confounding due to biases inherent in the design of observational studies.
Rauwolfia derivatives
The association between the use of rauwolfia derivatives, and breast cancer in women above the age of 50 was reported originally in 1974 [15, 25, 26] . Three case-control studies from Boston, Bristol and Helsinki reported similar results, indicting reserpine to cause breast cancer [15, 25, 26] . The initial reports raised serious concern and stimulated further studies scrutinizing the safety of reserpine as an antihypertensive agent. Three additional studies [6, 30, 35] confirmed the positive association between breast cancer and the use of rauwoflia derivatives. Our analysis of all published case-control studies found a statistically significant association between breast cancer and use of reserpine with an odds ratio of 1·25 (95% CI, 1·09-1·44). The clinical meaning of this association is unknown since reserpine is rarely used now. In addition, three longitudinal studies [37] [38] [39] failed to confirm the association between breast cancer and reserpine.
Since reserpine may elevate prolactin levels, it has been suggested that reserpine also might cause prostate
Odds ratio (95% CI)
Randomized controlled trials
Borhani et al. [49] Packer et al. [50] Gong et al. [51] Staessen et al. [52] Liu et al. [53] Pahor et al. [22] Pahor et al. [23] Jonas et al. [54] Hole et al. [55] Braun et al. [53] cancer [70] . However, at least two studies failed to observe an association between prostate cancer and use of reserpine [70, 71] . Reserpine use was also not associated with other types of malignancy [30] .
Diuretics
The observed data suggested an association between use of diuretic and renal cell cancer mainly in women. Studies carried out in animals indicated that the diuretic drugs, hydrochlorothiazide and furosemide, had a possible carcinogenic effect on the kidney [72] , as well as on other organs, though the effect was probably of small magnitude. Continuous treatment of rats with hydrochlorothiazide provoked massive degenerative changes in the distal converted module; these cells were reported to look like tumour cells and to express markers for tumour cells [73] .
The risk of renal cell carcinoma appeared to be related to the duration of the diuretic use [9, 11, 21] , while the average daily dose of the diuretic seemed to carry a lesser risk [20] . In some studies, the association between diuretic use and renal cell carcinoma became weaker when other risk factors, such as the presence of hypertension, were controlled statistically [9, 11, 12, 18, 41] . However, the association remained significant in five of 10 studies [17, [19] [20] [21] 40] . Diuretic use also was associated with renal cell carcinoma in normotensive subjects [19, 40] . A comparison that might be of interest is that of the risk of renal cancer attributable to diuretic therapy to that associated with hormonal replacement therapy (HRT) among menopausal women. Assuming 20% use of diuretics among hypertensive patients, with a doubling of the risk (our estimate among women) the attributable risk is 0·167. In comparison, assuming that the use of HRT is associated with a 20-25% increase in the risk of breast or endometrial cancer, if the frequency of HRT use among post-menopausal women is 25%, the attributable risk is estimated at 0·48 to 0·059. Even if the frequency were as large as 40%, the attributable risk would be 0·074 to 0·091. These figures suggest that, if real, the excess risk associated with diuretic use is greater, relative to the frequency of the cancer involved.
Unlike the association between diuretics and renal cell carcinoma, no association has been found between diuretic use and breast cancer [31, 32, 37] . Likewise, in the randomized controlled trial in elderly patients with isolated systolic hypertension (Systolic Hypertension in the Elderly Program [SHEP]), patients receiving diuretics had a similar rate of malignancies as those not receiving diuretics [5] .
Beta-blockers
Three randomized controlled trials raised concern that atenolol, a cardioselective beta-blocker, may increase mortality from malignancy [3, 44, 45] . In one case-control study [9] , the use of beta-blockers was associated with renal cell carcinoma in women.
Some laboratory studies have suggested that propranolol, a non-cardioselective beta-blocker, may be a possible promoter of malignancies at high doses and prolonged administration [74, 75] . Propranolol has been shown to increase liver tumour incidence in male rats when administered during treatment with 3 -methyl-4-dimethylminoazobenzene [76] or with diethylnitrosamine [77] . Zavanella et al., however, found no evidence that atenolol would promote liver carcinogenesis in rats pre-treated with diethylnitrosamine [74] . In contrast to the above observations, one longitudinal and three case control studies found no association between use of beta-blockers and malignancy [14, [46] [47] [48] .
In one of the studies [14] the incidence rate of renal cell carcinoma was increased in those receiving beta-blockers although this could have been related to additional diuretic use in the same patients [78] . This finding notwithstanding, the overall evidence from experimental and clinical studies regarding the association of beta-blocker therapy with malignancy is as yet inconclusive, but remains of concern.
Calcium antagonists
Calcium antagonists in high doses have been used to potentiate the antitumour effect of certain antineoplastic drugs [79] [80] [81] [82] [83] [84] . In animal models, calcium antagonists may reverse the resistance to antineoplastic drugs [85] . The increase in cytosolic calcium may play an important role in the regulation of cell proliferation [86] . Calcium antagonists have been shown to regulate calcium influx and thereby diminish proliferation of calcium-dependent neoplastic cells. These experimental data notwithstanding, in clinical studies there is some evidence that calcium antagonists may increase the risk of malignancy. In the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT) of 348 patients with coronary artery disease three patients died of carcinoma, all in the nifedipine group [87] . Recently, a few observational studies suggested that use of calcium antagonists could be associated with increased risk of malignancy [22] [23] [24] . In contrast to the above observations, five longitudinal studies found no association between calcium antagonists use and malignancy [14, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] 65] . Five randomized controlled trials showed an inverse association between calcium antagonist use and malignancy. This protective effect of calcium antagonists has to be investigated. Thus, the existing data make it unlikely that calcium antagonists increase the risk of malignancy.
Angiotensin converting enzyme (ACE) inhibitors
In several studies it was shown that in vitro captopril can inhibit the growth of neoplastic cells such as pancreatic
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ductal cancer cells [88] , human mammary carcinoma cells [89] , and human neuroblastoma cells [90] . In vivo, captopril treatment reduces the incidence and growth of radiation-induced cutaneous squamous cell carcinomas [91] , and sarcomas as well as the growth of hepatomas [92] . Despite the ability of ACE inhibitors to inhibit proliferation of neoplastic cells, there is indirect evidence that use of ACE inhibitors may be associated with increased cancer incidence or mortality. Several case reports described an association between the use of ACE inhibitors and malignancy [93] [94] [95] [96] [97] . In two case reports, captopril was associated with Kaposi's sarcoma [95, 97] , in one case report enalapril was associated with lung cancer [93] , and in two case reports captopril and enalapril were associated with mycosis fungoides-like lesions [95, 97] . In two randomized controlled trials ACE inhibitors appeared to be associated with increased mortality from cancer [58, 59] . In contrast, case control and longitudinal studies showed no relationship between use of ACE inhibitors and malignancy [14, 18, 22, 24, 48] . Most provocatively, in a recent longitudinal study, long-term use of ACE inhibitors seemed to exert a protective effect against malignancy [60] . Further large randomized controlled trials are required to evaluate the association between ACE inhibitors and malignancy.
Conclusion
The relationship between diuretic therapy and renal cell carcinoma is supported by biochemical, experimental, clinical, and epidemiological data. The relationship between rauwolfia and breast cancer, although statistically significant, is of little clinical concern because reserpine is no longer extensively used. The relationship between beta-blockers and malignancy is of concern but remains unproven. Recent clinical trials eliminated the proposed excess of cancer incidence among calcium antagonist users. Current data allow no firm conclusion with regard to the relationship between ACE inhibitors and malignancy. Given that differences in cardiovascular endpoints among various drug classes have been small and inconsistent, more attention should be paid to the effects of these drugs on extra-cardiovascular morbidity and mortality, such as malignancy.
